Health Care International - Affymax Completes Enrollment In PEARL 1, The First Of Four Phase 3 Clinical Trials Of Hematide™ To Treat Anemia In Chronic Renal Failure Patient
Affymax, Inc. (Nasdaq:AFFY) announced that enrollment has been completed in the first of four Phase 3 clinical trials of its lead investigational therapy, Hematide™, which is being evaluated for the treatment of anemia in chronic renal failure patie
Comments